Law Offices of Howard G. Smith announces an investigation on behalf of investors of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ: NLNK) concerning the Company and its officers’ possible violations of federal securities laws. Investors with losses on their NewLink investments are encouraged to contact Howard G. Smith, Esq. to discuss their legal rights.

NewLink, a biopharmaceutical company, purportedly focuses on discovering, developing and commercializing immunotherapeutic products to enhance treatment options for patients with cancer.

On May 9, 2016, post-market, NewLink disclosed that the Company's experimental pancreatic cancer immunotherapy algenpantucel-L failed to satisfy the main purpose of a late-stage study. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's phase III trial, compared to median survival of 30.4 months for patients treated with conventional therapy. And, these trial results demonstrate that patients might have actually been hurt by NewLink's treatment.

On this news, shares of NewLink fell $5.05 per share, or over 30%, to close on May 10, 2016 at $11.45 per share.

If you purchased NewLink securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.